Cytori Therapeutics is set to gain cancer drugs and a liposomal nanoparticle technology platform through the acquisition of Azaya Therapeutics. The lead drug is a formulation of doxorubicin, the ...

Cytori Therapeutics said today it plans to acquire the liposomal nanoparticle technology platform of Azaya Therapeutics for up to $170 million, in a deal designed to expand and complement the buyer’s ...

Cytori Therapeutics Inc. stock surged 7.9% to $1.78 per share in morning trade Thursday after the company said it had agreed to purchase assets from privately-held Azaya Therapeutics. Under the terms ...

Parexo Labs, a division of Azaya, launches as a new CDMO with an emphasis on nanotechnology and liposomal manufacturing. Azaya Therapeutics, a biopharmaceutical company focused on focused on ...